Comparing MiNK Therapeutics (NASDAQ:INKT) & Acumen Pharmaceuticals (NASDAQ:ABOS)

Acumen Pharmaceuticals (NASDAQ:ABOS) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Risk and Volatility

Acumen Pharmaceuticals has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.

Earnings and Valuation

This table compares Acumen Pharmaceuticals and MiNK Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.38)	-1.64
MiNK Therapeutics	N/A	N/A	-$22.46 million	($0.39)	-1.85

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Acumen Pharmaceuticals and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%
MiNK Therapeutics	N/A	N/A	-189.14%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Acumen Pharmaceuticals and MiNK Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	0	0	3	1	3.25
MiNK Therapeutics	0	0	2	0	3.00

Acumen Pharmaceuticals presently has a consensus price target of $9.00, suggesting a potential upside of 298.23%. MiNK Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 802.65%. Given MiNK Therapeutics’ higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Acumen Pharmaceuticals.

Institutional & Insider Ownership

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 19.7% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.